Sandercock Brett

CFO Brett Sandercock sells 3,000 RMD shares at $247.54; stock -11.6% in 30 days, -12.1% in 90 days.

Brett Sandercock, the Chief Financial Officer, sold 3,000 shares of ResMed (RMD) at $247.54 on 2025-11-03, reducing his holdings from 88.7K to 85.7K shares. Since the sale, the stock has declined -11.6% over 30 days and -12.1% over 90 days, now trading at $246.40, which is -16.1% from its 52-week high. His prior RMD sales show mixed timing: only 1 of 3 measurable 90-day outcomes was well-timed (negative return after sale), and his most recent RMD sell on 2025-10-01 was followed by a -10.0% 30-day decline while an earlier sell on 2025-05-22 was poorly timed with the stock rising +18.2% thereafter. The company's fundamentals remain solid with $1.3B quarterly revenue, +9.8% annual growth, and $348.5M net income, but the stock's significant recent weakness may warrant tracking whether this represents data-point discretionary selling or a broader reassessment of valuation near a 52-week peak.

CFO Brett Sandercock sold 3,000 RMD shares at $274.36 on 2025-10-01 for $823,080.00; retains 86,745 shares.

Sandercock sold 3,000 shares, reducing his holdings by 3.3%, while maintaining a substantial remaining position of 86.7K shares. The sale occurred at $274.36, approximately 1.5% below the current price of $278.59 and 6.5% below the 52-week high of $293.73. His cross-ticker track record shows 7 prior sells with a 40.00% well-timed rate and average 90-day return of -3.1%, though this ticker-specific pattern is mixed: at RMD, his 3 prior measurable 90-day outcomes were all positive (ranging +3.5% to +18.2%), indicating his prior RMD sales did not precede declines. The company maintains strong fundamentals with $1.3B in latest-quarter revenue, net income of $365.0M, and 9.8% annual revenue growth, trading at a P/E of 24.10.

RMD CFO Brett Sandercock sold 3,000 shares at $270.77 on 2025-09-02 for $812,310.00, retaining 87,745 shares post-transaction.

Sandercock sold 3,000 shares (3.3% of pre-transaction holdings) at $270.77, with RMD currently trading at $269.21, down 8.4% from its 52-week high and down 7.6% over the past 30 days. His prior RMD sales show mixed timing outcomes: at the 90-day horizon, he was well-timed on only 1 of 3 measurable sales, with a 33% success rate. His cross-ticker track record shows an average 90-day return of -5.2% after sells with a 50% well-timed rate, suggesting modest predictive ability. This sale falls within a recent pattern of three RMD dispositions in the past four months (May 22, July 1, August 1, and now September 2), though at smaller volumes; his continued retention of 87.7K shares indicates significant ongoing RMD exposure and does not suggest material loss of confidence in the company.

CFO Sandercock sells 3,000 RMD shares at $281.90; holds 83.3K shares post-sale.

Brett Sandercock, CFO of ResMed, sold 3,000 shares (a -3.5% reduction in holdings) for $845.7K at $281.90 on 2025-08-01. The stock has since climbed to $285.00, and over the prior 30 and 90 days has appreciated +10.9% and +16.5% respectively—positive momentum that contrasts with his cross-ticker track record: across all tickers, his 5 prior sales averaged -1.3% return at 30 days and -13.0% at 90 days, with a 66.67% well-timed rate. At RMD specifically, his most recent two sales (July and May 2025) have also been followed by gains (+5.8% and +3.7% at 30 days), a pattern that suggests these recent dispositions occurred during uptrends rather than prior to declines. The sale represents a modest portfolio adjustment from a CFO with substantial remaining holdings of 83.3K shares in a company posting strong fundamentals ($1.3B revenue, 11.0% annual growth, and a $41.8B market cap).

CFO Brett Sandercock sold 3,883 shares of RMD for $997,892.17 on 2025-07-01

Brett Sandercock, CFO of ResMed, sold 3,883 shares at $256.99, reducing his holdings from 88,166 to 84,283 shares. The sale occurred near the 52-week high of $258.00, with the stock currently trading at $255.88. Historically at RMD, Sandercock's prior three measurable sales showed mixed outcomes: two resulted in negative 90-day returns (-8.4% and -7.4% in May 2023; -23.1% and -19.6% respectively over 90 days), while one showed a modest positive 90-day return of +3.5% in 2024. Across his broader cross-ticker history, he has achieved a 66.67% well-timed sell rate, though his average 90-day return after sells was -13.0%, suggesting selective accuracy rather than consistent timing. The company remains financially healthy with revenue growth of +11.0% and a P/E of 28.56, providing no obvious fundamental distress signal.

RMD CFO Brett Sandercock sold 3,644 shares at $244.59 on 2025-05-22; post-sale holdings 86,283 shares.

Brett Sandercock, RMD's Chief Financial Officer, sold 3,644 shares (a -4.1% reduction in holdings) at $244.59 on 2025-05-22, retaining substantial exposure with 86,283 shares post-transaction. The company is posting strong fundamentals: $1.3B in latest-quarter revenue, $365.0M net income, and +11.0% annual revenue growth on a $36.1B market cap. Sandercock's same-ticker history at RMD shows mixed timing outcomes: his prior two 2023 sales both turned negative at the 90-day mark (posting -8.4% and -7.4% 30-day returns, then -23.1% and -19.6% 90-day returns), while his May 2024 sale saw modest gains (+3.5% at 90 days). His cross-ticker track record shows a 66.67% well-timed sell rate with -13.0% average 90-day return, indicating past sales have frequently preceded declines. The current stock is -4.4% from its 52-week high and +4.4% over 30 days, sitting near elevated valuations (P/E 27.48).